Proposal involving hospital use of methoxyflurane, COX-2 inhibitors and gabapentin
PHARMAC is seeking feedback on the following proposals for listings in Part II of Section H of the Pharmaceutical Schedule, to take effect from 1 July 2013:
- List methoxyflurane for use in painful procedures;
- List etoricoxib and celecoxib for perioperative use;
- Widen access to meloxicam to include perioperative use; and
- Widen access to gabapentin to include preoperative use.
The proposals in this consultation document relate to the proposed inclusion of pharmaceuticals and/or indications (as applicable) in the Hospitals Medicines List (HML) (Part II of Section H of the Pharmaceutical Schedule) from 1 July 2013. They do not relate to any existing or potential funding of any of these pharmaceuticals in the community (Section B of the Pharmaceutical Schedule).
Details of the proposals are provided on the following pages.
Feedback sought
PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by 5:00 pm on Friday 3 May 2013 to:
Geraldine MacGibbon
Senior Therapeutic Group Manager
PHARMAC
Email: geraldine.macgibbon@pharmac.govt.nz
Fax: 04 460 4995
Post: PO Box 10 254, Wellington 6143